T1	Limited_variation	12 40	TNF-a promoter polymorphisms
T2	Disease	63 81	multiple myeloma (
T3	Disease	82 91	MM ) were
T4	Phenotype	167 188	clinical outcome were
T5	Chemical	227 263	thalidomide and dexamethasone ( Thal
T6	Chemical	264 279	+ Dex ) regimen
R1	influences	Arg1:T1	Arg2:T2
R2	influences	Arg1:T1	Arg2:T3
R3	influences	Arg1:T1	Arg2:T4
R4	influences	Arg1:T1	Arg2:T5
R5	influences	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T2	Arg2:T1
R7	isEquivalentTo	Arg1:T2	Arg2:T3
R8	influences	Arg1:T2	Arg2:T4
R9	influences	Arg1:T2	Arg2:T5
R10	isAssociatedWith	Arg1:T3	Arg2:T1
R11	isEquivalentTo	Arg1:T3	Arg2:T2
R12	influences	Arg1:T3	Arg2:T4
R13	influences	Arg1:T3	Arg2:T5
R14	influences	Arg1:T3	Arg2:T6
R15	isAssociatedWith	Arg1:T4	Arg2:T1
R16	isAssociatedWith	Arg1:T4	Arg2:T2
R17	isAssociatedWith	Arg1:T4	Arg2:T3
R18	influences	Arg1:T4	Arg2:T5
R19	influences	Arg1:T4	Arg2:T6
R20	treats	Arg1:T5	Arg2:T2
R21	treats	Arg1:T5	Arg2:T3
R22	influences	Arg1:T5	Arg2:T4
R23	influences	Arg1:T5	Arg2:T6
R24	treats	Arg1:T6	Arg2:T2
R25	treats	Arg1:T6	Arg2:T3
R26	influences	Arg1:T6	Arg2:T4
R27	isEquivalentTo	Arg1:T6	Arg2:T5
